Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C.

ABSTRACT:

Background

Lymphocytic choriomeningitis virus (LCMV) belongs to the Arenavirus family known for inducing strong cytotoxic T-cell responses in both mice and humans. LCMV has been engineered for the development of cancer immunotherapies, currently undergoing evaluation in phase I/II clinical trials. Initial findings have demonstrated safety and an exceptional ability to activate and expand tumor-specific T lymphocytes. Combination strategies to maximize the antitumor effectiveness of LCMV-based immunotherapies are being explored.

Methods

We assessed the antitumor therapeutic effects of intratumoral administration of polyinosinic:polycytidylic acid (poly(I:C)) and systemic vaccination using an LCMV-vector expressing non-oncogenic versions of the E6 and E7 antigens of human papi

SUBMITTER: Gomar C 

PROVIDER: S-EPMC11029445 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature